Global Partners L.P. (GLP)
NYSE NYSE Primary 
Hims & Hers shares rally on results, but execs say GLP-1 drug shortage ‘is not abating'
Shares of Hims & Hers Health Inc. rallied after hours on Monday after the wellness platform bumped its full-year sales forecast higher, as its efforts to offer more personalized care and more weight-loss drugs continue to draw subscribers.
Could Buying This Weight Loss Stock Be Like Investing in Novo Nordisk At The Dawn of The GLP-1 Revolution?
Novo Nordisk dominates diabetes treatment and obesity care, but one clinical-stage pharma company could be the next breakout star.
Madrigal: Why I'm Having Doubts On The Bull Case Ahead Of Q3 Earnings
Madrigal's Rezdiffra, the first FDA-approved drug for MASH, shows promise but faces competition from GLP-1 drugs and financial challenges in launching in Europe. Despite meeting Phase 3 endpoints and early sales success, Madrigal's Q3 earnings will be crucial in determining Rezdiffra's commercial viability and stock performance. The potential for Rezdiffra to achieve blockbuster status is tempered by its high cost and the emerging threat of GLP-1 agonists in the MASH market.
Positive Partial 12-Week Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study
DehydraTECH-liraglutide and select DehydraTECH-CBD formulations were the top performing blood sugar groups KELOWNA, BC / ACCESSWIRE / October 24, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that it has received partial 12-week (final) blood sugar results from the recently completed animal study WEIGHT-A24-1 (the "Study"). Blood Sugar Levels (mmol/L) DehydraTECH Groups Day 7 Baseline Day 28 % Change to Day 28 Day 56 % Change to Day 56 Day 84 % Change to Day 84 A: CBD1 27.4 26.2 -4.31% 26.9 -1.90% 27.7 1.09% B: CBD2 28.4 29.2 2.73% 26.6 -6.22% 27.3 -3.76% C: CBD3 26.4 24.9 -5.99% 27.1 2.46% 27.5 3.85% D: CBD4 24.6 27.9 13.16% 26.8 8.94% 27.0 9.75% E: Rybelsus1 26.4 25.5 -3.60% 26.8 1.33% 26.8 1.59% w/SNAC F: Rybelsus2 24.9 26.8 7.70% 26.4 5.96% 27.3 9.58% w/SNAC G: Semaglutide 26.3 25.9 -1.52% 27.8 5.54% 26.9 2.13% No SNAC H: Liraglutide 26.4 25.8 -2.08% 25.2 -4.56% 23.3 -11.54% No SNAC Notes - Groups A through D were different DehydraTECH-CBD compositions - Groups E and F were reformulated Rybelsus DehydraTECH compositions - Groups G and H used pure GLP-1 drugs (semaglutide and liraglutide respectively) in DehydraTECH compositions - Recalculations led to slight changes from earlier reported data Lexaria is strongly encouraged that the DehydraTECH-liraglutide and DehydraTECH-CBD groups A and B outperformed all three of the Rybelsus® and pure semaglutide DehydraTECH composition groups regardless of whether the semaglutide had or had not been processed with the salcaprozate sodium technology known as "SNAC".
Structure Therapeutics: Potential To Have Best-In-Class GLP-1 Agonist For Obesity Patients
Positive 12-week data from phase 2a study of GSBR-1290 targeting obesity patients; significant placebo adjusted mean weight loss of 6.2% & 6.9% achieved for capsule and tablet respectively. One analyst believes that the market for obesity treatments could expand to $200 billion by 2031. The 36-week phase 2b study, using GSBR-1290 for the treatment of patients with obesity, expected to start in Q4 of 2024.
Positive Partial 12-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study
Lexaria Bioscience Corp. (NASDAQ:LEXX) & (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that it has received partial 12-week (final) body weight results from the recently completed animal study WEIGHT-A24-1 (the "Study").
1 Healthcare Giant That Isn't Jumping on the GLP-1 Bandwagon, and Why That Could Be a Great Move
Novartis is taking a more calculated and strategic approach to its growth.
GLP-1 Stocks Aren't the Only Way to Benefit From the Weight Loss Drugs Boom
The future of the weight loss market might not revolve around GLP-1 drugs.
WeightWatchers stock price skyrockets on news that it will offer a compounded GLP-1 weight-loss drug like Wegovy
WeightWatchers announced on Tuesday that it will offer a compounded version of Novo Nordisk‘s popular weight-loss drug Wegovy as part of its weight-management programs, a move that sent its shares soaring nearly 47%.
Lexaria's GLP-1 Human Pilot Study #3 Begins Dosing
DehydraTECH-processed tirzepatide from Zepbound® is being tested in an oral dose format KELOWNA, BC / ACCESSWIRE / October 9, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce that dosing has begun, for human pilot study #3 (the "Study"), investigating a DehydraTECH-processed version of the dual action GLP-1 (glucagon-like peptide) + GIP (glucose-dependent insulinotropic peptide) Zepbound® (tirzepatide) in an oral dose format. The Study is being conducted in up to 10 healthy volunteers.
WeightWatchers' stock soars after adding compounded GLP-1 treatment to its offering
“With the addition of compounded semaglutide [GLP-1], we are expanding our offering to include a clinical weight management solution that is both accessible and affordable,” said Interim Chief Executive Tara Comonte in prepared remarks.
GLP Capital Partners and Ares Management Corp to Merge in $5.2 Billion Deal
GLP Group has announced the merger of its fund management business, GLP Capital Partners (GCP), with Ares Management Corporation, a leading alternative asset management company listed on the New York Stock Exchange. The merger includes GCP's international operations in Japan, the United States, Europe, Brazil, and Vietnam.
